The adoption of legislation for the Joint EU HTA Assessment heralds a new era in healthcare evaluation. Starting January 2025, the Joint Clinical Assessment (JCA) will be implemented for cancer and Advanced Therapy Medicinal Products (ATMPs), significantly impacting access planning in the industry.
In this context, our Managing Director, Anand Jha, moderated a crucial session at the Pharma Marcon conference in Berlin on October 7, 2024. He was joined by esteemed panelists Sandeep Kiri, Stephanie Dr. med. Rosenfeld, Inka Heikkinen, and Thomas Grub. The discussion focused on the challenges companies face regarding access planning and effective strategies to address these issues.
The session explored various aspects that industry stakeholders are currently navigating, fostering a constructive dialogue on health policy and patient access.
